Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis.
Brain Behav Immun Health
; 37: 100752, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38524897
ABSTRACT
Accumulating evidence suggests that the Epstein-Barr virus (EBV) plays a key role in the development of multiple sclerosis (MS). Additionally, depressive symptoms often precede the onset of MS. Given the role of the XBP1-sigma-1 receptor complex in the endoplasmic reticulum during EBV reactivation, the author proposes that fluvoxamine, an antidepressant with sigma-1 receptor agonism, could be a suitable therapeutic drug for MS.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article